Longeveron LLCLGVN
± MixedCapitalrelevance
Reverse stock split is a structural adjustment, not operational change; impact on stock price is neutral.
Impact on stocks 1
Biotech & Genomic Medicine
Longeveron LLCLongeveron Inc. announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on August 26, 2026. The split was approved by stockholders on July 1, 2026 and by the board on July 31, 2026, and the Class A shares are expected to begin trading on a split-adjusted basis on Nasdaq on August 27, 2026 under the existing ticker LGVN. The move is intended to raise the per-share price to regain compliance with Nasdaq's $1.00 minimum bid requirement. The reverse split will reduce outstanding Class A shares from approximately 30,432,974 to approximately 3,043,298, and Class B shares from approximately 1,449,005 to approximately 144,901, with no fractional shares issued and any fractional interests rounded up at the DTC participant level. CEO Stephen Willard said the split is a structural adjustment that does not change operations or stockholder value, and is expected to better align the stock with institutional investor preferences.
Longeveron LLCReverse stock split is a structural adjustment, not operational change; impact on stock price is neutral.